Plain-English translation of NCT07811908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a clinical trial testing a new combination malaria medication called + in children ages 2 to 12 who have uncomplicated malaria. The trial compares this new treatment head-to-head against the standard malaria medication (artemether + lumefantrine) that doctors typically use today. Researchers want to see if the medication is safe, well-tolerated, and effective at treating malaria parasites.
Current malaria treatments work, but doctors are always looking for better options—medications that might work faster, require fewer doses, or have fewer side effects. This trial tests whether this new treatment could be a meaningful improvement for children with malaria.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new medication or the standard malaria treatment, both taken by mouth. The study will check how well the medication works, how safe it is, and how your body processes it by doing blood tests and monitoring your health over time. Your child will be watched closely during and after treatment to make sure the medication is working and not causing problems.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Burkina Faso
Côte d’Ivoire
Gabon